Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A5 | Q9Y345 | 2/20 | 0.68 |
| ▸ | CASP2 | P42575 | 1/20 | 0.61 |
| ▸ | FAAH | O00519 | 4/20 | 0.58 |
| ▸ | NAAA | Q02083 | 1/20 | 0.57 |
| ▸ | PAOX | Q6QHF9 | 1/20 | 0.57 |
| ▸ | DNM1 | Q05193 | 2/20 | 0.55 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.54 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.54 |
| ▸ | RELA | Q04206 | 2/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27856043 | 1.00 | SLC6A5 (0.68) | SLC6A5CASP2FAAHNAAAPAOX | |
| SCHEMBL27591402 | 1.00 | SLC6A5 (0.68) | SLC6A5CASP2FAAHNAAAPAOX | |
| SCHEMBL18721509 | 1.00 | SLC6A5 (0.68) | SLC6A5CASP2FAAHNAAAPAOX | |
| SCHEMBL12085671 | 1.00 | SLC6A5 (0.68) | SLC6A5CASP2FAAHNAAAPAOX | |
| SCHEMBL18721508 | 1.00 | SLC6A5 (0.68) | SLC6A5CASP2FAAHNAAAPAOX | |
| SCHEMBL12951398 | 1.00 | SLC6A5 (0.68) | SLC6A5CASP2FAAHNAAAPAOX | |
| SCHEMBL194531 | 1.00 | SLC6A5 (0.68) | SLC6A5CASP2FAAHNAAAPAOX | |
| SCHEMBL3817465 | 0.98 | SLC6A5 (0.70) | SLC6A5CASP2FAAHNAAAPAOX | |
| SCHEMBL15065357 | 0.98 | SLC6A5 (0.70) | SLC6A5CASP2FAAHNAAAPAOX | |
| SCHEMBL30823020 | 0.98 | SLC6A5 (0.66) | SLC6A5CASP2FAAHNAAAPAOX |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260069537-A1 | Stable Aqueous Bendamustine Cyclodextrin Composition | SOFTKEMO PHARMA CORP (CA) | 2026-03-12 | — | — | US | disclosed |
| EP-4587002-A1 | LYOPHILIZED BENDAMUSTINE-CYCLODEXTRIN COMPOSITION | Softkemo Pharma Corp. (CA) | 2025-07-23 | — | — | EP | disclosed |
| US-20240148696-A1 | LYOPHILIZED BENDAMUSTINE-CYCLODEXTRIN COMPOSITION | SOFTKEMO PHARMA INC. (CA) | 2024-05-09 | — | — | US | disclosed |
| WO-2024091826-A1 | LYOPHILIZED BENDAMUSTINE-CYCLODEXTRIN COMPOSITION | SOFTKEMO PHARMA INC. (CA) | 2024-05-02 | — | — | WO | disclosed |
| US-20220265829-A1 | FORMULATIONS OF BENDAMUSTINE | EAGLE PHARMACEUTICALS, INC. | 2022-08-25 | — | — | US | disclosed |
| US-20200368355-A1 | FORMULATIONS OF BENDAMUSTINE | EAGLE PHARMACEUTICALS, INC. (US) | 2020-11-26 | — | — | US | disclosed |
| US-20180185488-A1 | FORMULATIONS OF BENDAMUSTINE | EAGLE PHARMACEUTICALS INC (US) | 2018-07-05 | — | — | US | disclosed |
| EP-2792369-B1 | Bendamustine cyclopolysaccharide compositions | SOFTKEMO PHARMA CORP (CA) | 2018-04-18 | — | — | EP | disclosed |
| EP-2792369-A1 | Bendamustine cyclopolysaccharide compositions | SUPRATEK PHARMA, INC. (CA) | 2014-10-22 | — | — | EP | disclosed |
| EP-2400987-B1 | BENDAMUSTINE CYCLOPOLYSACCHARIDE COMPOSITIONS | SUPRATEK PHARMA INC (CA) | 2014-09-03 | — | — | EP | disclosed |
| US-8703964-B2 | Bendamustine cyclopolysaccharide compositions | SUPRATEK PHARMA INC. (CA) | 2014-04-22 | — | — | US | disclosed |
| CN-102421451-B | Bendamustine cyclopolysaccharide compositions | SUPRATEK PHARMA INC | 2013-11-06 | — | — | CN | disclosed |
| US-20130190372-A1 | BENDAMUSTINE CYCLOPOLYSACCHARIDE COMPOSITIONS | SUPRATEK PHARMA INC. (CA) | 2013-07-25 | — | — | US | disclosed |
| US-8436032-B2 | Bendamustine cyclopolysaccharide compositions | SUPRATEK PHARMA INC. (CA) | 2013-05-07 | — | — | US | disclosed |
| CN-102935080-A | Bendamustine cyclopolysaccharide compositions | SUPRATEK PHARMA INC | 2013-02-20 | — | — | CN | disclosed |
| CN-102421451-A | Bendamustine cyclopolysaccharide compositions | SUPRATEK PHARMA INC | 2012-04-18 | — | — | CN | disclosed |
| EP-2400987-A1 | BENDAMUSTINE CYCLOPOLYSACCHARIDE COMPOSITIONS | SUPRATEK PHARMA, INC. (CA) | 2012-01-04 | — | — | EP | disclosed |
| WO-2010097700-A1 | BENDAMUSTINE CYCLOPOLYSACCHARIDE COMPOSITIONS | SUPRATEK PHARMA, INC. (CA) | 2010-09-02 | — | — | WO | disclosed |
| US-20100216858-A1 | BENDAMUSTINE CYCLOPOLYSACCHARIDE COMPOSITIONS | SOFTKEMO PHARMA CORP. (CA) | 2010-08-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200368355-A1 | FORMULATIONS OF BENDAMUSTINE | FOLR2, BHMT, THPO | SLC6A5 277/4885CASP2 680/4885FAAH 3918/4885 |
| US-20180185488-A1 | FORMULATIONS OF BENDAMUSTINE | FOLR2, BHMT, THPO | SLC6A5 277/4885CASP2 680/4885FAAH 3918/4885 |
| US-20260069537-A1 | Stable Aqueous Bendamustine Cyclodextrin Composition | TBCD, CTNND1, KIT | SLC6A5 178/4885CASP2 1365/4885FAAH 4726/4885 |
| US-20220265829-A1 | FORMULATIONS OF BENDAMUSTINE | FOLR2, BHMT, THPO | SLC6A5 277/4885CASP2 680/4885FAAH 3918/4885 |
| US-20240148696-A1 | LYOPHILIZED BENDAMUSTINE-CYCLODEXTRIN COMPOSITION | SORD, SBK1, SBDS | SLC6A5 760/4885CASP2 3118/4885FAAH 4829/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.